The FDA has granted its approval to Natroba Topical Suspension 0.9%, a new treatment for controlling head lice.
According to the U.S. Centers for Disease Control and Prevention, there are between 6 to 12 million cases of head lice infestations each year, mostly in children 3 to 12 years old in the US. Head lice are contagious, blood-sucking parasites which leaps from head to head, going through an entire classroom in one day. The adult louse has developed a resistance to methods of killing it, making it very difficult to get rid of. The money spent to deal with this condition is as high as $1 billion per year in the US alone.
Natroba proves to be an effective treatment, for in two 10 minute applications, with a week's interval in between, 86% of the people tested became lice-free. It has its side effects in the redness and irritation of the eyes and skin. Moreover, as it contains benzyl alcohol, it could cause death in infants.
Nevertheless, this is the only effective treatment that is available now.